Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2009

View Archived Issues

Activity seen with eniluracil and 5-fluorouracil in hepatocellular carcinoma

Ferric carboxymaltose improves restless legs syndrome in double-blind study

Fate Therapeutics acquires intellectual property rights to osteogenic agents from UC

Morphotek and Synageva sign research collaboration for therapeutic monoclonal antibodies

Clopidogrel with aspirin reduces vascular event risk in atrial fibrillation patients

Study tests carotid plaque inflammation biomarker, atorvastatin effects

High response rates to RFB4(dsFv)-PE38 treatment in hairy cell leukemia

Actelion receives E.U. approval for pediatric dispersible formulation of Tracleer for PAH

Alcon initiates treatment in phase II trial of NovaBay's NVC-422 for viral conjunctivitis

Salvat launches antibiotic Cetraxal for otitis externa in the U.S.

Genentech reports results from phase III BRAVO study of Lucentis in branch RVO

GSK discontinues development of Kissei's SGLT2 inhibitor remogliflozin for diabetes

Sigma-Tau submits MAA to EMEA for antimalarial Eurartesim

Novartis enrolls first patient in phase III study of Sosei's NVA-237 for COPD

FDA approves Lilly's Alimta as maintenance therapy for NSCLC

Eisai to initiate U.S. clinical trial of Dacogen in pediatric AML

Initial tender offer for Cougar Biotechnology completed by Johnson & Johnson

Oxigene to acquire Symphony Vida and rights to OXi-4503 and Zybrestat for ophthalmology

BioCis Pharma reports results from phase IIa clinical trial of ProtoCure in dermatitis

Action Pharma discovers and patents novel melanocortin receptor ligands

Cellzome presents PI3Kgamma inhibitors for the treatment of immunological disorders

Polyamine analogues active against Enterocytozoon bieneusi in mouse model

Bar-Ilan University patent describes novel P2Y1 receptor agonists

Cubist initiates dosing in CONSERV-2 clinical trial of ecallantide for blood loss in surgery

CBP-501 initiates phase II clinical studies for non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...